A3P Biomedical AB

Stockholm3 abstract wins 1[st] prize at European Association of Urology

Wed, Jul 14, 2021 09:07 CET

STOCKHOLM, July 14, 2021. An abstract presenting the STHLM3 MR trial was awarded the “1[st] Prize Best Abstract Oncology 2021” at the annual European Association of Urology meeting. The trial included 12,750 men and concluded that combining the Stockholm3 test with MRI for prostate cancer screening decreases overdetection by 69% compared to Standard of Care, while maintaining detection of significant cancer.In total, 4,000 abstracts were presented at the annual European Association of Urology, the largest scientific meeting in Europe within the field of Urology. The abstract “Risk-adapted

Prostate cancer screening with Stockholm3 reduces unnecessary biopsies and is cost-effective

Mon, Mar 22, 2021 09:00 CET

STOCKHOLM, March 22, 2021. A3P Biomedical announced today that an independent and peer reviewed study showed health economic benefits using Stockholm3 versus PSA in a screening by invitation setting for prostate cancer. The results from the study demonstrated that Stockholm3 reduced unnecessary biopsies and was cost-effective compared to screening with the currently used PSA test.In previous peer-reviewed studies, e.g. the pivotal STHLM3 study on 58,000 men published in Lancet Oncology, the Stockholm3 test demonstrated significant health benefits compared to PSA (current standard of care)

Share

Stockholm3 abstract wins 1[st] prize at European Association of Urology

Prostate cancer screening with Stockholm3 reduces unnecessary biopsies and is cost-effective